Drug
REP 2139 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Studies by the year they started
3 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Replicor Inc. (3)
Often tested with
Tested in the same studies.
REP 2165 (1) · Thymalfasin (1) · Peginterferon alfa-2a (1)
Studies
Open first, then newest update. How each study uses REP 2139 is read from its arms, and is right about nine times in ten.
Testing it · 3
- REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B InfectionCompletedPhase 2Replicor Inc.NCT02565719Written as REP 2139-Mg
- Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis BCompletedPhase 2Replicor Inc.NCT02726789Written as REP 2139-Ca
- Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected PatientsCompletedPhase 1/2Replicor Inc.NCT02646189Written as REP 2139-Ca
Codes
What other systems call REP 2139 · ClinicalTrials.gg INT032016
- MeSH (NLM) C000628017REP 2139One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628017 | REP 2139 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.